Dentsply Sirona (NASDAQ:XRAY) received mixed analyst ratings with an upward trend in price targets, indicating a positive outlook. The average 12-month price target is $40.25, reflecting a 21.97% increase from the previous $33.00. Analysts from Needham and Leerink Partners maintain or announce optimistic ratings, while Piper Sandler holds a neutral stance. Despite financial challenges like negative revenue growth and below-average net margin, the company's market capitalization and debt management are strong. Dentsply Sirona's diverse product portfolio in dental equipment and supplies positions it as a significant player in the healthcare sector.